Huge upside with this one!!Ibogaine is a naturally derived plant molecule and can be effective in significantly reducing and even eliminating detoxification withdrawal symptoms as part of the overall addiction treatment and therapy process. The use of ibogaine and other psychedelics for medical and addiction treatments is expected to significantly expand globally in the next decade. The Company plans to undertake clinical development, and subsequently obtain regulatory authorization for the use of ibogaine as an authorized addiction interruption medicine, initially for the treatment of Opioid Use Disorder(s). The Company plans to ultimately submit a Clinical Trial Application (“CTA”) to Health Canada, with the intent of demonstrating ibogaine safety and efficacy in clinical trials. UI is currently seeking to secure a supplier / manufacturer of GMP certified ibogaine for in sufficient quantities for use in the planned clinical trials. The Company’s primary goals are 1) to submit a CTA to Health Canada in the short-term, to be permitted to undertake clinical trials to prove the safety and efficacy of ibogaine assisted detoxification, initially for the treatment of Opioid Use Disorder(s), in order to eventually have ibogaine approved for wide-spread addiction treatment, and 2) to build a foundation of addiction treatment clinics, initially utilizing a combination of innovative non-psychedelic detox methods and holistic treatments, growing from the one initial location that was acquired in 2021.